Vertex impresses with strong Trikafta launch

Vertex on Thursday put an exclamation mark to the earlier-than-expected U.S. approval of its new cystic fibrosis drug Trikafta, reporting fourth quarter revenues five times higher than what Wall Street had expected from the Massachusetts biotech.